ASTRIS: A multicenter, real world treatment study of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Cheema, P. K. [1 ]
Chen, Y-M. [2 ]
de Marinis, F. [3 ]
Freitas, H. C. [4 ]
Kim, S-W. [5 ]
Milner, A. [6 ]
Provencio, M. [7 ]
Rigas, J. [6 ]
Wu, Y-L. [8 ]
机构：
[1] Sunnybrook HSC, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[2] Natl Yang Ming Univ, Taipei, Taiwan
[3] Ist Europeo Milan, Div Thorac Oncol, Milan, Italy
[4] AC Camargo Canc Ctr, Sao Paulo, Brazil
[5] Asan Med Ctr, Seoul, South Korea
[6] AstraZeneca, Cambridge, England
[7] Hosp Clin Barcelona, Barcelona, Spain
[8] Guangdong Gen Hosp, Guangdon Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
141TiP
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Real-Life Data of Osimertinib in Pretreated Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
    Alfaro Autor, C.
    Romero, A.
    Calvo De Juan, V.
    Franco, F.
    Sanchez Romero, E.
    Ortiz Cortes, N.
    Sanz Moreno, S.
    Rodriguez Festa, A.
    Serna Blasco, R.
    Barquin Del Romo, M.
    Provencio, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1036 - S1036
  • [42] OSIMERTINIB COMBINED WITH CETUXIMAB FOR NON-SMALL CELL LUNG CANCER (NSCLC) WITH T790M AND C797S MUTATIONS
    Chia-Ling, Chang
    Jin-Yuan, Shih
    RESPIROLOGY, 2018, 23 : 169 - 170
  • [43] Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer
    Wang, Nannan
    Wang, Linlin
    Meng, Xiangjiao
    Wang, Jia
    Zhu, Lifang
    Liu, Changting
    Li, Shaorong
    Zheng, Li
    Yang, Zhenfan
    Xing, Ligang
    Yu, Jinming
    ONCOLOGY REPORTS, 2019, 41 (01) : 77 - 86
  • [44] Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
    Schmid, S.
    Klingbiel, D.
    Aeppli, S.
    Britschgi, C.
    Gautschi, O.
    Pless, M.
    Rothschild, S.
    Wannesson, L.
    Janthur, W.
    Foerbs, D.
    Demmer, I.
    Jochum, W.
    Fruth, M.
    LUNG CANCER, 2019, 130 : 149 - 155
  • [45] Real-world data on efficacy and safety of osimertinib in non-small cell lung cancer patients with EGFR T790M mutation detected by first and repeat rebiopsy
    Wang, Yuenan
    Zhang, Huanhuan
    Zou, Yuxia
    Ren, Xueru
    Wang, Hanqi
    Bai, Rubing
    Xu, Ke
    Xu, Yehong
    Zhang, Zhihong
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 (06) : 715 - 722
  • [46] Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M-positive non-small cell lung cancer
    Kim, Hye Sook
    Lim, Kun Young
    Lee, Soo-Hyun
    Kim, Hyae Young
    Lee, Youngjoo
    Han, Ji-Youn
    CANCER MEDICINE, 2023, 12 (11): : 12285 - 12298
  • [47] Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients
    Alexeyenko, Andrey
    Brustugun, Odd Terje
    Eide, Inger Johanne Zwicky
    Gencheva, Radosveta
    Kosibaty, Zeinab
    Lai, Yi
    de Petris, Luigi
    Tsakonas, Georgios
    Grundberg, Oscar
    Franzen, Bo
    Viktorsson, Kristina
    Lewensohn, Rolf
    Hydbring, Per
    Ekman, Simon
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (10) : 2064 - +
  • [48] Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer
    Lin, Yi-Tsz
    Chu, Chia-Yu
    LUNG CANCER, 2019, 129 : 110 - 111
  • [49] Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer
    John, Thomas
    Bowden, Jeffrey J.
    Clarke, Stephen
    Fox, Stephen B.
    Garrett, Kerryn
    Horwood, Keith
    Karapetis, Christos S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (04) : 296 - 303
  • [50] SAFETY AND EFFICACY OF OSIMERTINIB AS A THERAPY IN PATIENTS WITH EGFR T790M POSITIVE NON SMALL CELL LUNG CANCER PATIENTS: A SYSTEMATIC REVIEW
    Gadi, H. R.
    Ganta, M. R.
    Voleti, V. B.
    Rayavarapu, J. E.
    Thatavarti, R.
    VALUE IN HEALTH, 2017, 20 (09) : A418 - A418
12345